Product Details
| Alternative Name: | UBE2C, Ubiquitin-protein ligase C |
| |
| MW: | ~19.7kDa |
| |
| Source: | Produced in E. coli. |
| |
| UniProt ID: | O00762 |
| |
| Formulation: | Liquid. In PBS. |
| |
| Purity: | ≥95% (SDS-PAGE) |
| |
| Application Notes: | E2 conjugating enzyme for ubiquitinylation reactions. |
| |
| Shipping: | Dry Ice |
| |
| Short Term Storage: | -80°C |
| |
| Long Term Storage: | -80°C |
| |
| Use/Stability: | Stable for at least 1 year after receipt when stored, as supplied, at -80°C. |
| |
| Handling: | Avoid freeze/thaw cycles. After opening, prepare aliquots and store at -80°C. |
| |
| Scientific Background: | The anaphase-promoting complex (APC) coordinates mitosis by sequentially promoting the degradation of key cell-cycle regulators via the ubiquitin-proteasome pathway, utilizing the ubiquitin E2 conjugating enzyme UbcH10 and K11-linked polyubiquitin chain modification of substrate proteins. Following the degradation of its substrates, the APC catalyzes the autoubiquitination of UbcH10 resulting in its degradation and subsequent inactivation of the APC.
Aberrant performance or modulated cellular levels of UbcH10 or any of its associated components is likely to have significant consequences for cell cycle regulation.
UbcH10 expression has been shown to be a valid indicator of the proliferative and aggressive status of thyroid carcinomas and its overexpression is thought to play a role ovarian carcinogenesis. In contrast expression levels of UbcH10 are extremely low in many normal cells.
Such observations suggest the possibility of using UbcH10 detection as a marker for the diagnosis and prognosis of neoplastic diseases and open the possibility of a therapy of some carcinomas based on the suppression of the UbcH10 synthesis and/or function. |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Coomassie stained gel of UbcH10 (5µg, BML-UW0960)
Please mouse over
Product Literature References
Regulated interaction of ID2 with the anaphase-promoting complex links progression through mitosis with reactivation of cell-type-specific transcription: S.B. Lee, et al.; Nat. Commun.
13, 2089 (2022),
Abstract;
UBE2L3, a Partner of MuRF1/TRIM63, Is Involved in the Degradation of Myofibrillar Actin and Myosin: D. Peris-Moreno, et al.; Cells
10, 1974 (2021),
Abstract;
General Literature References
Identification of a physiological E2 module for the human anaphase-promoting complex: A. Williamson, et al.; PNAS U.S.A.
106, 18213 (2009),
Abstract;
UbcH10 expression may be a useful tool in the prognosis of ovarian carcinomas: M.T. Berlingieri, et al.; Oncogene
26, 2136 (2007),
Abstract;
The processivity of multiubiquitination by the APC determines the order of substrate degradation: M. Rape, et al.; Cell
124, 890 (2006),
Abstract;
A novel UbcH10-binding protein facilitates the ubiquitinylation of cyclin B in vitro: F. Kobirumaki, et al.; J. Biochem.
137, 133 (2005),
Abstract;
UbcH10 overexpression may represent a marker of anaplastic thyroid carcinomas: P. Pallante, et al.; Br. J. Cancer
93, 464 (2005),
Abstract;
Autonomous regulation of the anaphase-promoting complex couples mitosis to S-phase entry: M. Rape & M.W. Kirschner; Nature
432, 588 (2004),
Abstract;
UbcH10 is the cancer-related E2 ubiquitin-conjugating enzyme: Y. Okamoto, et al.; Cancer Res.
63, 4167 (2003),
Abstract;
Structural and functional analysis of the human mitotic-specific ubiquitin-conjugating enzyme, UbcH10: Y. Lin, et al.; J. Biol. Chem.
277, 21913 (2002),
Abstract;
